Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Odeon Acquires China Rights for Two Cancer Therapies in $200 Million Deal

publication date: Feb 22, 2022

Odeon Therapeutics, a Hong Kong-Shanghai biopharma, has acquired China rights for two cancer therapies from Taiwan's OBI Pharma in a $200 million agreement. Odeon will develop OBI-999, a novel antibody-drug conjugate, and OBI-833, a therapeutic cancer vaccine  targeting the tumor antigen Globo H. Both candidates target a wide variety of solid tumor cancers. Odeon will make a $12 million upfront payment to OBI and pay up to $188 million in milestones, plus royalties. It will be responsible for all China development costs. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here